Penn Capital Management Company LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 351,408 shares of the biopharmaceutical company's stock, valued at approximately $10,577,000. Penn Capital Management Company LLC owned 0.23% of TG Therapeutics at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after buying an additional 209,190 shares in the last quarter. Clearbridge Investments LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter worth $55,237,000. Charles Schwab Investment Management Inc. raised its position in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after buying an additional 84,904 shares during the period. Invesco Ltd. lifted its position in TG Therapeutics by 1.2% in the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after buying an additional 10,989 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock valued at $27,797,000 after acquiring an additional 87,679 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have issued reports on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.
Read Our Latest Report on TGTX
TG Therapeutics Stock Performance
Shares of TGTX traded up $1.03 on Friday, reaching $41.33. 1,464,365 shares of the stock traded hands, compared to its average volume of 3,086,120. The firm has a market cap of $6.56 billion, a price-to-earnings ratio of -413.26 and a beta of 2.14. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The stock's 50-day moving average price is $37.18 and its 200-day moving average price is $32.52. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. Equities analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
